|
|
Article: Use of methotrexate for autoimmune hearing loss
- Article from:
- The Annals of Otology, Rhinology & Laryngology
- Article date:
- August 1, 2000
- Author:
CopyrightCopyright Annals Publishing Company Aug 2000. Provided by ProQuest LLC. (Hide copyright information)
|
To assess the efficacy of low-dose methotrexate (MTX) given long-term for the treatment of autoimmune hearing loss, we performed a prospective open-label study of 11 patients with treatment-refractory autoimmune hearing loss. All patients had ongoing episodic worsening of hearing in I or both ears before enrollment despite traditional medical therapy. The MTX dose was 7.5 to 17.5 mg/wk. Hearing loss and vertigo were evaluated at baseline and at completion of the study. Hearing improvement was defined as an improvement in the pure tone threshold (PT) average of >10 dB or an increase in speech discrimination (SD) of >15%, whereas worsening was defined as a worsening of >10 dB in PT ...